Fosaprepitant Placebo

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Chemotherapy-Induced Nausea and Vomiting (CINV)Chemotherapy-induced Nausea and Vomiting

Phase 2

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)

CompletedNCT01697579

Merck Sharp & Dohme LLCChemotherapy-induced Nausea and Vomiting

Start: 2012-12-13End: 2016-11-21Updated: 2019-06-25

Phase 3

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

CompletedNCT01594749

Merck Sharp & Dohme LLCChemotherapy-Induced Nausea and Vomiting (CINV)

Start: 2012-09-24End: 2014-11-03Updated: 2018-09-04

Related Papers

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type

BMC Cancer2020-09-259 citations

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.

2018-05-288 citations

Abstract P6-11-11: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer receiving moderately emetogenic chemotherapy regimens

Cancer Research2018-02-152 citations

Pharmacokinetics/pharmacodynamics (PK/PD), safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric subjects.

Journal of Clinical Oncology2017-11-01

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based therapies.

Journal of Clinical Oncology2017-05-20

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

2015-10-0855 citations

A phase III, randomized, double-blind study of single-dose intravenous fosaprepitant in preventing chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.

Journal of Clinical Oncology2015-05-203 citations

Phase III design for a trial of single-dose fosaprepitant (FA) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).

Journal of Clinical Oncology2014-05-20